EC Number   |
Application |
Reference |
|---|
    3.5.4.5 | diagnostics |
evaluation of CDA genotype may be helpful in screening patients before treatment, in order to identify subjects with slower CDA-mediated gemcitabine metabolism |
700510 |
| 3.5.4.5 | drug development |
CDA is a target for development of specific enzyme inhibitors with potential anti-proliferative activity on cell growth of Mycobacterium tuberculosis, the major causative agent of tuberculosis |
-, 718695 |
| 3.5.4.5 | medicine |
- |
209669 |
| 3.5.4.5 | medicine |
activation and inactivation of several deoxycytidine antimetabolites |
209533, 209534 |
| 3.5.4.5 | medicine |
cytidine deaminase as prognostic marker in non-small-cell lung cancer. In the patients with high versus low CDA activity the response rate is 25.0% and 54.1%, the 6-month progression rate is 34.5% and 54.1%, the 1-year survival rate is 23.3% and 57.3%, respectively |
753114 |
| 3.5.4.5 | medicine |
different effect of cytidine in blood cells from healthy donors and chronic lymphocytic and acute myeloblastic leukemia patients |
209643, 209659 |
| 3.5.4.5 | medicine |
enzyme limits the effectiveness of the antineoplastic agent cytosine arabinoside or aracytidine in the treatment of acute myeloblastic leukemias, chemotherapeutic use of the inhibitor THU to protect antileukemic agents from deaminase attack, inhibitors of cytidine deaminase prolongs the plasma halflife of antitumor or antiviral drugs |
209645, 209649, 209661, 209662, 209663 |
| 3.5.4.5 | medicine |
studies on radiosensitization of glioblastoma multiforme (GBM), deoxynucleoside analogue gemcitabine (dFdC) considered for combination therapy with radiation in glioblastomas |
695606 |
